QCI Interpret for Oncology

Precision medicine for any cancer assay on any platform

864 views
May 29, 2019
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences. QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000). N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests. Join us for an informative webinar about both clinical interpretation solutions.

Interested in learning more?

Click here


Speakers: Dan Richards, Ph.D., Vice President of Biomedical Informatics at QIAGEN Sheryl Elkin, Ph.D., Chief Scientific Officer of N-of-One, Inc.Less

Related videos

QCI Interpret for Oncology

Rapid, evidence-based reporting of oncology NGS tests at scale

75 views December 08, 2021

Competing to offer a comprehensive genomic profiling service for solid or...

QCI Interpret for Oncology

Gaining insights with transcriptomic profiling and mechanistic modeling

233 views June 11, 2021

In this webinar, Moritz Schütte, head of next-generation sequencing data...

QCI Interpret for Oncology

Going beyond: Molecular evidence for off-label therapy use

103 views June 02, 2021

Kathryn Bungartz, Ph.D., Associate StaffField Application Scientist, QIAGEN...

QCI Interpret for Oncology

Confidence and trust: Deliver valuable clinical insights with high-quality knowledge

105 views June 02, 2021

Ben Turner, Director of Bioinformatics Enterprise Solutions, QIAGEN Digital...